The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Topoisomerase I inhibition in BRCA+ and BRCA- ovarian cancer (OC): A single-institution experience.
D. M. Hyman
No relevant relationships to disclose
Q. Zhou
No relevant relationships to disclose
A. G. Arnold
No relevant relationships to disclose
R. N. Grisham
No relevant relationships to disclose
J. Bhatia
No relevant relationships to disclose
C. Aghajanian
No relevant relationships to disclose
A. Iasonos
No relevant relationships to disclose
D. R. Spriggs
No relevant relationships to disclose
N. D. Kauff
Consultant or Advisory Role - Pfizer
Expert Testimony - Pfizer